BJ 023
Alternative Names: BJ-023Latest Information Update: 05 Jul 2022
At a glance
- Originator BJ Bioscience
- Class Anti-infectives; Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Infections
Highest Development Phases
- Preclinical Autoimmune disorders; Infections
Most Recent Events
- 05 Jul 2022 BJ 023 is available for licensing in World as of 05 Jul 2022. https://www.bjbioscience.com/en/expand#block-body-2
- 05 Jul 2022 Preclinical trials in Autoimmune disorders in China (Parenteral), prior to July 2022 (BJ Biosciences pipeline, July 2022)
- 05 Jul 2022 Preclinical trials in Infections in China (Parenteral), prior to July 2022 (BJ Biosciences pipeline, July 2022)